MCID: PPT005
MIFTS: 58

Peptic Ulcer Disease

Categories: Gastrointestinal diseases

Aliases & Classifications for Peptic Ulcer Disease

MalaCards integrated aliases for Peptic Ulcer Disease:

Name: Peptic Ulcer Disease 12 15
Peptic Ulcer 36 29 54 42 44 71
Acute Peptic Ulcer Without Hemorrhage and Without Perforation 12
Acute Peptic Ulcer with Hemorrhage and Perforation 12
Acute Peptic Ulcer with Hemorrhage 12

Classifications:



External Ids:

Disease Ontology 12 DOID:750
KEGG 36 H01634
ICD9CM 34 533
MeSH 44 D010437
NCIt 50 C3318
SNOMED-CT 67 155701001
ICD10 32 K27
UMLS 71 C0030920

Summaries for Peptic Ulcer Disease

MedlinePlus : 42 A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse. To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Peptic Ulcer Disease, also known as peptic ulcer, is related to gastrointestinal ulceration, recurrent, with dysfunctional platelets and active peptic ulcer disease, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Peptic Ulcer Disease is S100A8 (S100 Calcium Binding Protein A8), and among its related pathways/superpathways are PEDF Induced Signaling and Cytokine Signaling in Immune system. The drugs Potassium citrate and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include small intestine, pancreas and cortex, and related phenotypes are Reduced mammosphere formation and cardiovascular system

KEGG : 36 Peptic ulcer is a common disorder of gastrointestinal system characterized by mucosal damage secondary to pepsin and gastric acid secretion. It usually occurs in the stomach and proximal duodenum. Typical symptoms include episodic burning epigastric pain, loss of appetite, and weight loss. Pain usually occurs two to five hours after meals or on an empty stomach. The most common causes of peptic ulcer are Helicobacter pylori infection and use of nonsteroidal anti-inflammatory drugs (NSAIDs). Smoking increases the risk of ulcer recurrence and slows healing. Most patients are treated successfully with eradication of H. pylori and/or avoidance of NSAIDs, along with the appropriate use of antisecretory therapy. About 25 percent of patients with peptic ulcer have a serious complication such as hemorrhage, perforation, or gastric outlet obstruction. Administration of proton pump inhibitors (PPIs) and endoscopic therapy control most bleeds.

Wikipedia : 74 Peptic ulcer disease (PUD) is a break in the inner lining of the stomach, the first part of the small... more...

Related Diseases for Peptic Ulcer Disease

Diseases related to Peptic Ulcer Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 821)
# Related Disease Score Top Affiliating Genes
1 gastrointestinal ulceration, recurrent, with dysfunctional platelets 32.3 S100A8 PTGS2 PTGS1 HRH2 GAST
2 active peptic ulcer disease 32.3 PTGS2 PTGS1 HRH2 CYP2C19 ATP4A
3 multiple endocrine neoplasia, type i 32.0 SCT MEN1 GHRL GAST
4 zollinger-ellison syndrome 32.0 SCT MEN1 HRH2 GRP GAST ATP4A
5 peptic ulcer perforation 31.8 S100A8 HRH2 ATP4A
6 helicobacter pylori infection 31.7 TNF IL1RN IL1B IL10 CYP2C19 CXCL8
7 duodenitis 31.5 TNF S100A8 GAST ATP4A
8 opisthorchiasis 31.1 TNF IL1B CXCL8
9 gastric adenocarcinoma 31.0 TP53 S100A8 PTGS2 HRAS GAST
10 duodenal ulcer 31.0 TNF SCT S100A8 IL1RN IL1B IL10
11 gastroduodenitis 31.0 GAST ATP4A
12 peritonitis 30.9 TNF IL1B IL10 CXCL8
13 dumping syndrome 30.9 SCT GHRL GAST
14 gastric ulcer 30.9 TP53 TNF S100A8 PTGS2 PTGS1 IL1RN
15 duodenogastric reflux 30.9 SCT GAST ATP4A
16 microinvasive gastric cancer 30.9 TP53 S100A8 GAST ATP4A
17 irritable bowel syndrome 30.9 TNF IL1B IL10 GHRL CXCL8
18 atherosclerosis susceptibility 30.8 TNF PPARG IL1B CXCL8
19 gastric lymphoma 30.8 TP53 S100A8 ATP4A
20 lymphoma, mucosa-associated lymphoid type 30.8 TP53 S100A8 CXCL8 ATP4A
21 bile reflux 30.7 SCT S100A8 PTGS2 GAST ATP4A
22 end stage renal disease 30.7 TNF IL1RN IL1B IL10
23 aortic aneurysm, familial abdominal, 1 30.7 TNF IL1B IL10 CXCL8
24 ileus 30.7 TNF IL1B IL10 GHRL
25 superior mesenteric artery syndrome 30.7 HRH2 ATP4A
26 aspiration pneumonitis 30.7 TNF HRH2 CXCL8 ATP4A
27 bronchitis 30.7 TNF IL1B IL10 CXCL8
28 liver cirrhosis 30.7 TP53 TNF SCT PPARG IL1B IL10
29 anthracosis 30.6 TNF IL1B CXCL8
30 esophagitis 30.6 TP53 TNF PTGS2 IL1B IL10 HRH2
31 stomach disease 30.6 PTGS2 PTGS1 HRH2 GHRL
32 gastrinoma 30.6 SCT MEN1 GRP GAST
33 chronic kidney disease 30.6 TNF PPARG IL1B IL10 GHRL CXCL8
34 obstructive jaundice 30.6 TNF GRP CXCL8
35 rosacea 30.5 TNF S100A8 CXCL8
36 hernia, hiatus 30.5 HRH2 GHRL GAST CYP2C19 ATP4A
37 islet cell tumor 30.5 SCT MEN1 GAST
38 gastric cancer 30.5 TP53 S100A8 PTGS2 IL1RN IL1B HRH2
39 pancreatitis 30.5 TNF SCT IL1B IL10
40 diarrhea 30.5 TNF SCT IL1B IL10 HRH2 GAST
41 peptic esophagitis 30.5 TNF S100A8 PTGS2 IL1B HRH2 GAST
42 gastroenteritis 30.5 TNF IL1RN IL1B IL10 HRH2 CXCL8
43 enterocolitis 30.4 TNF IL10 CXCL8
44 hepatitis a 30.4 TNF IL1B IL10
45 stomatitis 30.4 TNF IL1B IL10 CXCL8
46 pulmonary disease, chronic obstructive 30.4 TNF IL1B IL10 CXCL8
47 urticaria 30.4 TNF PTGS2 PTGS1 HRH2
48 appendicitis 30.4 TNF IL1B IL10 CXCL8
49 spondylitis 30.4 TNF IL1B IL10
50 preterm premature rupture of the membranes 30.4 TNF IL1B IL10 CXCL8

Comorbidity relations with Peptic Ulcer Disease via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Peptic Ulcer Disease:



Diseases related to Peptic Ulcer Disease

Symptoms & Phenotypes for Peptic Ulcer Disease

UMLS symptoms related to Peptic Ulcer Disease:


nausea and vomiting, constipation, abdominal pain, diarrhea, dyspepsia, icterus, signs and symptoms, digestive, heartburn, gastrointestinal gas

GenomeRNAi Phenotypes related to Peptic Ulcer Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 ATP4A CXCL8 GHRL HRAS MEN1 PPARG

MGI Mouse Phenotypes related to Peptic Ulcer Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.14 GRP HRAS IL10 IL1B IL1RN MEN1
2 homeostasis/metabolism MP:0005376 10.13 ATP4A GAST GHRL GRP HRAS HRH2
3 digestive/alimentary MP:0005381 10.11 ATP4A GAST GHRL HRAS HRH2 IL10
4 endocrine/exocrine gland MP:0005379 10.1 ATP4A GAST GHRL HRAS HRH2 IL10
5 integument MP:0010771 9.81 HRAS IL10 IL1B IL1RN PPARG PTGS1
6 muscle MP:0005369 9.56 HRAS IL10 MEN1 PPARG PTGS1 PTGS2
7 neoplasm MP:0002006 9.36 ATP4A GAST HRAS IL10 IL1B MEN1

Drugs & Therapeutics for Peptic Ulcer Disease

Drugs for Peptic Ulcer Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
2
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
3
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
4
Clarithromycin Approved Phase 4 81103-11-9 84029
5
Coal tar Approved Phase 4 8007-45-2
6
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
7
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
8
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
9
Azithromycin Approved Phase 4 83905-01-5 55185 447043
10
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
11
Metronidazole Approved Phase 4 443-48-1 4173
12
Ofloxacin Approved Phase 4 82419-36-1 4583
13
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
14
Misoprostol Approved Phase 4 59122-46-2 5282381
15
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
16
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
17
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
18
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 3435 5323714
19 Analgesics, Non-Narcotic Phase 4
20 Anti-Inflammatory Agents Phase 4
21 Cyclooxygenase Inhibitors Phase 4
22 Fibrinolytic Agents Phase 4
23 Anti-Inflammatory Agents, Non-Steroidal Phase 4
24 Antirheumatic Agents Phase 4
25 Analgesics Phase 4
26 Antipyretics Phase 4
27 Purinergic P2Y Receptor Antagonists Phase 4
28 Respiratory System Agents Phase 4
29 Cytochrome P-450 CYP3A Inhibitors Phase 4
30 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
31 Erythromycin Estolate Phase 4
32 Erythromycin stearate Phase 4
33 Erythromycin Ethylsuccinate Phase 4
34 Cyclooxygenase 2 Inhibitors Phase 4
35 Antitubercular Agents Phase 4
36 diuretics Phase 4
37 Expectorants Phase 4
38 Antibiotics, Antitubercular Phase 4
39 Cytochrome P-450 Enzyme Inhibitors Phase 4
40 Anti-Infective Agents Phase 4
41 Anti-Bacterial Agents Phase 4
42 Anticoagulants Phase 4
43 Antiparasitic Agents Phase 4
44 Antiprotozoal Agents Phase 4
45 Anti-Infective Agents, Local Phase 4
46 Monoamine Oxidase Inhibitors Phase 4
47
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
48
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
49
Deferiprone Approved Phase 2, Phase 3 30652-11-0 2972
50
Iron Approved Phase 2, Phase 3 7439-89-6 23925 29936

Interventional clinical trials:

(show top 50) (show all 173)
# Name Status NCT ID Phase Drugs
1 Phase IV Study Comparing Helicobacter Pylori Empiric Eradication With Test-Guided Treatment in Patients With Peptic Ulcer Bleeding Unknown status NCT00687336 Phase 4
2 A Double Blind Study Comparing Low Dose and High Dose IV Esomeprazole After Successful Endoscopic Therapy in Patients With Peptic Ulcer Bleeding Unknown status NCT01275937 Phase 4 Esomeprazole;esomeprazole
3 Compare Gastric Acid Suppression of Esomeprazole by Oral or Intravenous Administration - A Randomized Trial Unknown status NCT00471029 Phase 4 esomeprazole
4 Protective Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Unknown status NCT02175186 Phase 4 ALBIS;Placebo
5 A Clinical Study of the Efficacy of Esomeprazole or Rabeprazole on the Pattern of Release of Pro- and Anti-inflammatory Cytokines From Gastric Mucosa of Patients With Peptic Ulcer Disease Completed NCT00534443 Phase 4
6 Sequential Versus Concomitant Therapy for Helicobacter Pylori Infection Completed NCT00656968 Phase 4 10-day sequential treatment;10-day concomitant therapy
7 A Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers Completed NCT01353144 Phase 4 aspirin
8 The Therapeutic Role of Albumin Supply on Peptic Ulcer Bleeding and the Correlation Between Clinical Course and Expression of Serum Response Factor on Ulcer Tissue and Superoxide Free Radical in Blood Completed NCT01822600 Phase 4 Human albumin;Omeprazole
9 Comparison of Conventional Triple Therapy Versus Sequential Therapy for H. Pylori in Peptic Ulcer Disease: Prospective Randomized Trial Completed NCT01418300 Phase 4 sequential versus triple
10 The Feasibility of Fast-track Surgery for Perforated Peptic Ulcers. A Prospective Randomized Clinical Trial Completed NCT01620671 Phase 4
11 Effects of 2 Different Doses of Pantoprazole on Gastric pH and Recurrent Bleeding in Patients Who Bled From Peptic Ulcers Completed NCT00279123 Phase 4 pantoprazole infusion;pantoprazole bolus;no treatment
12 Phase 4 Study of Intravenous Proton Pump Inhibitor in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy- a Prospective Randomized Comparative Trial Completed NCT00731601 Phase 4 pantoprazole;pantoprazole
13 Comparison of Hemostatic Efficacy for Argon Plasma Coagulation vs Hemoclipping Following Distilled Water Injection in Treating High-risk Bleeding Ulcers Completed NCT04366583 Phase 4
14 The Dissemination of Consensus Recommendations on the Management of Canadian Patients With Non Variceal Upper Gastrointestinal Bleeding: A National Cluster Randomized Trial of a Multifaceted Tailored Implementation Strategy Completed NCT00840008 Phase 4
15 The Studies of the Pathophysiologic Mechanisms of Poor Ulcer Healing & Clinical Improvement to the High Ulcer Rebleeding Rate for Patients With Comorbid Illnesses Completed NCT01591083 Phase 4 esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)
16 Famotidine vs. Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion - a Randomized Controlled Study Completed NCT00843063 Phase 4 pantoprazole vs famotidine
17 Administration of Intravenous Proton Pump Inhibitor Prior to Endoscopy [APPE] in Patients With Upper Gastrointestinal Bleeding; a Double-Blind Placebo-Controlled Randomised Study. Completed NCT00164866 Phase 4 Omeprazole
18 Eradication of Helicobacter Pylori According to 23S rRNA Point Mutations Associated With Clarithromycin Resistance Completed NCT01453036 Phase 4
19 Prevention of Recurrent Idiopathic Gastroduodenal Ulcer Bleeding: a Double-blind Randomized Trial Completed NCT01180179 Phase 4 Lansoprazole;Famotidine
20 The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in Helicobacter Pylori Patients Completed NCT02648659 Phase 4 Ilaprazole;Amoxicillin;Clarithromycin;Metronidazole
21 Comparison of High Dose Infusion and Low Dose Bolus Intravenous Omeprazole for Treatment of Bleeding Ulcer With Adherent Clot Completed NCT02536989 Phase 4 omeprazole;omeprazole
22 Comparison of Azithromycin or Clarithromycin in 3drugs Protocol of H-pylori Eradication Regimen Completed NCT01667692 Phase 4 azithromycin;clarithmycin
23 A Multicenter, Randomized, Active-Controlled Comparison Study of the Incidence of Gastroduodenal Ulcers Associated With Celecoxib and Low Dose ASA Versus Naproxen and Low Dose ASA in Healthy Subjects (50-75 Years of Age) Completed NCT00137033 Phase 4 Celecoxib;Naproxen;ASA
24 Prospective, Randomized Controlled Trial Comparing Amoxicillin and Metronidazole Based Bismuth-containing Quadruple Therapy With Amoxicillin and Clarithromycin Based Quadruple Therapy for First-line Helicobacter Pylori Eradication Completed NCT02175901 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Amoxicillin;Metronidazole;Clarithromycin
25 A Randomized, Double-blind Clinical Trial Comparing Zegerid Capsule to Famotidine in Preventing Anastomotic (Marginal) Ulcers in Post Gastric Bypass Patients Completed NCT00557349 Phase 4 Omeprazole;Famotidine
26 A Randomized, Blinded, Placebo-Controlled Study of the Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on Gastroduodenal Healing Completed NCT00778193 Phase 4 Naproxen;Aspirin;Celecoxib;Clopidogrel;Placebo
27 Helicobacter Pylori Eradication With Berberine Hydrochloride, Lansoprazole, Amoxicillin and Bismuth Versus Clarithromycin Bismuth, Lansoprazole and Amoxicillin: A Randomized, Open-label, Non-inferiority, Phase Ⅳ Trial Completed NCT02633930 Phase 4 Berberine;clarithromycin;Bismuth;Lansoprazole;amoxicillin
28 Helicobacter Pylori Treatment Completed NCT01668927 Phase 4 Proton Pump Inhibitor;Bismuth;Metronidazole;Tetracycline;Furazolidone;Amoxicillin
29 Levofloxacin-containing Therapy for Helicobacter Pylori Treatment Completed NCT01667718 Phase 4 Bismuth;Lansoprazole;Levofloxacin;Amoxicillin
30 Ivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan Completed NCT02241044 Phase 4
31 Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori Completed NCT01667575 Phase 4 Esomeprazole;Amoxicillin;Clarithromycin;Bismuth Potassium Citrate
32 Helicobacter Pylori Eradication With Berberine Hydrochloride,Esomeprazole,Amoxicillin and Clarithromycin Versus Bismuth,Esomeprazole,Amoxicillin,and Clarithromycin: a Randomized,Open-label, Non-inferiority, Phase Ⅳ Trail Completed NCT02296021 Phase 4 Berberine;Bismuth;esomeprazole;amoxicillin;clarithromycin
33 Intravenous Administration of Metronidazole, Levofloxacin and Esomeprazole Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease Recruiting NCT04432233 Phase 4 Esomeprazole;Metronidazole;Levofloxacin
34 Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer: a Double-blind Randomised Trial on Misoprostol Combined With Lansoprazole Versus Lansoprazole Alone (NRT_MISO Study) Recruiting NCT03675672 Phase 4 Misoprostol Oral Tablet;Placebo Oral Tablet
35 Secondary Prevention With Long-term Oral Esomeprazole for Peptic Ulcer Recurrence and Rebleeding in High-risk Rockall Scores ≥ 6 Patients Enrolling by invitation NCT02456012 Phase 4 oral esomeprazole 20 mg twice daily;oral esomeprazole 20 mg once daily
36 A Multi-centre, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Phase 4 Efficacy and Safety Study of P-CAB (Tegoprazan 50 mg Once Daily) Compared With PPI (Rabeprazole 20 mg Once Daily) to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease Not yet recruiting NCT04416581 Phase 4 PPI;P-CAB 25;P-CAB 50
37 Rescue Therapy for Helicobacter Pylori Eradication: A Randomized and Non-inferiority Trail of High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy Not yet recruiting NCT04678492 Phase 4 Esomeprazole;Amoxicillin;Bismuth;Esomeprazole;Tetracycline;Furazolidone
38 Effect of High-dose Oral Rabeprazole on Recurrent Bleeding After the Endoscopic Treatment of Bleeding Peptic Ulcers Terminated NCT00838682 Phase 4 omeprazole sodium IV;Rabeprazole
39 Low Dose Against High Dose of Proton Pump Inhibitors in Treatment Acute Peptic Ulcer Bleeding Withdrawn NCT02724150 Phase 4 Omeprazole High dose;Omeprazole Low dose
40 Oral vs Intravenous Proton Pump Inhibitor(PPI) in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy- a Prospective Randomized Comparative Trial Withdrawn NCT01123031 Phase 4 lansoprazole;esomeprazole
41 A Prospective, Randomized Trial Comparing the Effect of Intravenous Omeprazole to That of Intravenous Ranitidine on the Maintenance of Hemostasis After Successful Endoscopic Treatment of Bleeding Peptic Ulcer Withdrawn NCT00247130 Phase 4 Omeprazole;Ranitidine
42 Clinical Effectiveness of Intravenous Esomeprazole Versus Pantoprazole in Preventing Peptic Ulcer Recurrent Bleeding: a Double-Blind Randomized Trial Withdrawn NCT00881413 Phase 4 Esomeprazole;Pantoprazole
43 Evaluation of the Efficacy and Safety of Different Duration of Proton Pump Inhibitor for Prevention of Upper Gastrointestinal Mucosal Injury in Patients Taking 12-month Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery Withdrawn NCT03038009 Phase 4 Pantoprazole
44 Oral Versus Intravenous Proton Pump Inhibitor Treatment in High-risk Bleeding Peptic Ulcers After Endoscopic Hemostasis: a Prospective Randomized Comparative Study Unknown status NCT01182597 Phase 3 Pantoprazole (Pantoloc);Lansoprazole (Takepron OD)
45 Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone, and Incretin Based Therapy Unknown status NCT02882477 Phase 2, Phase 3 Deferiprone;Acetylcysteine;Sitagliptin and Metformin
46 Comparison of the Percentage Chronic on-Demand Users Treated With 20 Mg Pantoprazole on-Demand and Placebo o.d Versus Placebo on-Demand and 20 Mg Pantoprazole o.d. After Symptom Relief With 20 Mg Pantoprazole o.d. Unknown status NCT00161096 Phase 3 pantoprazole 20 mg (drug)
47 Intravenous Infusion of High Dose Omeprazole Versus Regular Dose Omeprazole on Recurrent Bleeding After Endoscopic Treatment of Bleeding Peptic Ulcers Completed NCT00519519 Phase 3 Omeprazole
48 An Efficacy and Safety Study of Intravenous Pantoprazole in the Prevention of Recurrent Peptic Ulcer Bleeding After Successful Hemostasis Completed NCT00040495 Phase 3 Pantoprazole
49 A Randomised, Double-blind, Parallel-group, Placebo Controlled Study of Esomeprazole i.v. (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour) Administered for 72 Hours to Assess Prevention of Rebleeding in Subjects That Have Undergone Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer - the PUB Study. Completed NCT00251979 Phase 3 Esomeprazole
50 Phase 3 Study of Prospective Randomized Trial Comparing Adjunctive High Dose Omeprazole Infusion Against Scheduled Second Endoscopy in the Prevention of Peptic Ulcer Rebleeding After Therapeutic Endoscopy Completed NCT00164931 Phase 3 Intravenous omeprazole infusion

Search NIH Clinical Center for Peptic Ulcer Disease

Inferred drug relations via UMLS 71 / NDF-RT 51 :


clidinium
Clidinium bromide
Glycine
Glycopyrrolate
Hyoscyamine
Hyoscyamine hydrobromide
Hyoscyamine Sulfate
Methscopolamine
methscopolamine bromide
methscopolamine nitrate
Propantheline
Propantheline Bromide

Cochrane evidence based reviews: peptic ulcer

Genetic Tests for Peptic Ulcer Disease

Genetic tests related to Peptic Ulcer Disease:

# Genetic test Affiliating Genes
1 Peptic Ulcer 29

Anatomical Context for Peptic Ulcer Disease

MalaCards organs/tissues related to Peptic Ulcer Disease:

40
Small Intestine, Pancreas, Cortex, Adrenal Cortex, Liver, Colon, Pituitary

Publications for Peptic Ulcer Disease

Articles related to Peptic Ulcer Disease:

(show top 50) (show all 22021)
# Title Authors PMID Year
1
Banxia Xiexin Decoction in the treatment of Hp-associated peptic ulcer: A protocol for systematic review and meta-analysis. 61 42
33466180 2021
2
Therapeutic efficacy and safety of Kangfuxin in combination with rabeprazole in the treatment of peptic ulcer: A systematic review and meta-analysis. 61 42
33235070 2020
3
Psychological effect of comprehensive nursing intervention in elderly patients with perforated peptic ulcer: A protocol of systematic review. 61 42
32991417 2020
4
In situ expression of cagA and risk of gastroduodenal disease in Helicobacter pylori-infected children. 61 54
20038850 2010
5
DNA sequence analysis of cagA 3' motifs of Helicobacter pylori strains from patients with peptic ulcer diseases. 61 54
19850704 2010
6
[Results of evaluating the functional state of the gastric mucosa in duodenal peptic ulcer by means of a test gastropanel in workers engaged in the manufacture of nitrogen compounds]. 61 54
20387669 2010
7
Diverse characteristics of the CagA gene of Helicobacter pylori strains collected from patients from southern vietnam with gastric cancer and peptic ulcer. 61 54
19846630 2009
8
Distribution of Helicobacter pylori virulence markers in patients with gastroduodenal diseases in Pakistan. 61 54
19930551 2009
9
[Guidelines of prevention and treatment for NSAID-related peptic ulcers]. 61 54
19934612 2009
10
Disease association with two Helicobacter pylori duplicate outer membrane protein genes, homB and homA. 61 54
19545429 2009
11
Detection and evaluation of antibodies against neutrophil-activating protein of Helicobacter pylori in patients with gastric cancer. 61 54
19452583 2009
12
[Therapeutic and preventive effects of sulfate-chloride-sodium mineral water in experimental peptic ulcer]. 61 54
19639693 2009
13
Helicobacter pylori cagA status and peptic ulcer disease in Iran. 54 61
18612816 2009
14
[Genetic features of Helicobacter pylori at patients with duodenal ulcer]. 61 54
20469711 2009
15
Helicobacter pylori and non-malignant diseases. 61 54
18783518 2008
16
Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib. 61 54
18711705 2008
17
Zollinger-Ellison syndrome: a personal perspective. 61 54
18646472 2008
18
vacA genotypes of Helicobacter pylori in relation to cagA status and clinical outcomes in Iranian populations. 61 54
18653971 2008
19
Differences in virulence markers between Helicobacter pylori strains from Iraq and those from Iran: potential importance of regional differences in H. pylori-associated disease. 54 61
18353934 2008
20
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. 61 54
18381949 2008
21
Future expectations in the prophylaxis of intestinal bleeding. 61 54
18346690 2008
22
Peptic ulceration may be a hormonal deficiency disease. 54 61
18280672 2008
23
Epidemiology of acute upper gastrointestinal bleeding. 61 54
18346679 2008
24
Prevalence of cagA in relation to clinical presentation of Helicobacter pylori infection in Egypt. 54 61
19086246 2008
25
Preferential induction of transforming growth factor-beta production in gastric epithelial cells and monocytes by Helicobacter pylori soluble proteins. 61 54
17922404 2007
26
Association between Helicobacter pylori genotypes and gastric disorders in relation to the cag pathogenicity island. 54 61
17521839 2007
27
Helicobacter pylori cagA and iceA genotypes status and risk of peptic ulcer in Saudi patients. 54 61
17334464 2007
28
Gastrinoma--morphological aspects. 61 54
17985091 2007
29
Helicobacter pylori cag pathogenicity island genes: clinical relevance for peptic ulcer disease development in Brazil. 61 54
17172510 2007
30
Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. 61 54
17088110 2006
31
Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. 61 54
17006979 2006
32
Association of H pylori cagA and vacA genotypes and IL-8 gene polymorphisms with clinical outcome of infection in Iranian patients with gastrointestinal diseases. 54 61
16937534 2006
33
Significance of cagA status and vacA subtypes of Helicobacter pylori in determining gastric histopathology: virulence markers of H. pylori and histopathology. 61 54
16724992 2006
34
[Microbiologic, serologic diagnosis, and genotypification of Helicobacter pylori isolated from biopsies in children and adult people. Molecular detection of the cag pathogenicity island of Helicobacter pylori]. 54 61
17578080 2006
35
Lower prevalence of Helicobacter pylori infection with vacAs1a, cagA-positive, and babA2-positive genotype in erosive reflux esophagitis disease. 61 54
16302983 2005
36
No correlation of babA2 with vacA and cagA genotypes of Helicobacter pylori and grading of gastritis from peptic ulcer disease patients in Brazil. 61 54
16302986 2005
37
Clinical and pathological importance of vacA allele heterogeneity and cagA status in peptic ulcer disease in patients from North Brazil. 61 54
16444419 2005
38
Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection. 54 61
16268979 2005
39
[BabA2, oipA and cagE Helicobacter pylori genotypes in Colombian patients with gastroduodenal diseases]. 61 54
16276680 2005
40
Distinct diversity of vacA, cagA, and cagE genes of Helicobacter pylori associated with peptic ulcer in Japan. 54 61
16081930 2005
41
Clinical Relevance of the vacA, iceA, cagA, and flaA genes of Helicobacter pylori strains isolated in Eastern Taiwan. 54 61
15956417 2005
42
cagA gene variants in Malaysian Helicobacter pylori strains isolated from patients of different ethnic groups. 61 54
15866222 2005
43
Distribution of Helicobacter pylori cagA, cagE and vacA in different ethnic groups in Kuala Lumpur, Malaysia. 61 54
15836708 2005
44
cagA vacA alelles and babA2 genotypes of Helicobacter pylori associated with gastric disease in Brazilian adult patients. 54 61
15808313 2005
45
Zollinger-Ellison phenotype in the absence of hypergastrinemia and islet-cell tumor. 61 54
15879632 2005
46
Gastrointestinal effects of selective and non-selective non-steroidal anti-inflammatory drugs. 54 61
15892675 2005
47
Distribution of vacA alleles and cagA status of Helicobacter pylori in peptic ulcer disease and non-ulcer dyspepsia. 54 61
15606640 2004
48
Genetic polymorphism of interleukin-8 (IL-8) is associated with Helicobacter pylori-induced duodenal ulcer. 54 61
15627645 2004
49
Helicobacter pylori density and cagA status in cirrhotic patients: a case-control study. 61 54
15377296 2004
50
Diversity of vacA and cagA genes of Helicobacter pylori in Japanese children. 54 61
15298599 2004

Variations for Peptic Ulcer Disease

Expression for Peptic Ulcer Disease

Search GEO for disease gene expression data for Peptic Ulcer Disease.

Pathways for Peptic Ulcer Disease

Pathways related to Peptic Ulcer Disease according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.68 TP53 TNF PTGS2 PTGS1 IL1RN IL1B
2
Show member pathways
13.33 TP53 TNF PTGS2 IL1RN IL1B IL10
3
Show member pathways
13.05 TP53 TNF IL1B IL10 HRAS CXCL8
4
Show member pathways
12.93 TP53 TNF PTGS2 IL1B HRAS CXCL8
5
Show member pathways
12.68 TNF PTGS2 IL1RN IL1B HRAS CXCL8
6
Show member pathways
12.57 TP53 TNF IL1B IL10 HRAS
7 12.47 TNF PTGS2 PTGS1 IL1RN IL1B IL10
8 12.39 TP53 TNF IL1B CXCL8
9
Show member pathways
12.32 PTGS2 PPARG HRH2 HRAS
10
Show member pathways
12.29 TP53 TNF PTGS2 PTGS1 IL1B
11 12.26 TP53 PPARG MEN1 CXCL8
12
Show member pathways
12.25 TNF PTGS2 IL1B IL10
13
Show member pathways
12.25 TP53 TNF IL1B IL10 CXCL8
14 12.22 TNF IL1B DEFB4A CXCL8
15
Show member pathways
12.21 TP53 TNF PTGS2 IL1B HRAS CXCL8
16
Show member pathways
12.18 TNF IL1B DEFB4A CXCL8
17
Show member pathways
12.16 TNF PTGS2 IL1B IL10 HRAS
18
Show member pathways
12.13 TNF S100A8 PTGS2 IL1B DEFB4A CXCL8
19 12.1 TNF IL1RN IL1B IL10 CXCL8
20 12.07 TNF IL1B IL10 CXCL8
21 11.97 PTGS2 PTGS1 HRAS CYP2C19
22 11.92 TP53 IL1B HRAS CXCL8
23 11.91 TNF PTGS2 IL1B CXCL8
24 11.89 TNF IL1B IL10 CXCL8
25 11.88 TNF IL1B HRAS CXCL8
26 11.88 TP53 TNF PTGS2 IL1B CXCL8
27 11.78 TNF IL1B IL10
28
Show member pathways
11.75 TNF IL1B IL10
29 11.74 TNF IL1B IL10
30 11.73 TP53 HRAS CXCL8
31 11.73 TNF IL1B IL10 CXCL8
32
Show member pathways
11.72 TNF PTGS2 PPARG CXCL8
33 11.66 TNF IL1B CXCL8
34 11.62 PTGS2 PTGS1 PPARG
35
Show member pathways
11.61 TNF PTGS2 IL1B CXCL8
36 11.6 TNF IL1B CXCL8
37 11.55 TP53 PTGS2 CXCL8
38 11.51 TNF PTGS2 HRAS
39 11.49 TP53 TNF PTGS2 IL1B IL10 CXCL8
40 11.47 TP53 TNF HRAS
41 11.46 TNF IL1B IL10 CXCL8
42 11.37 TNF IL1B IL10
43 11.34 TNF IL1B IL10
44 11.24 TNF IL1B IL10
45 10.79 TNF PTGS2 IL1RN IL1B IL10 CXCL8
46 10.74 TNF PTGS2 PTGS1 CXCL8
47 10.39 SCT GRP GAST
48 10.13 HRH2 GAST ATP4A

GO Terms for Peptic Ulcer Disease

Cellular components related to Peptic Ulcer Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 TNF SCT S100A8 IL1RN IL1B IL10
2 extracellular space GO:0005615 9.4 TNF SCT S100A8 IL1RN IL1B IL10

Biological processes related to Peptic Ulcer Disease according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.26 PPARG IL1RN IL1B IL10 HRH2 HRAS
2 G protein-coupled receptor signaling pathway GO:0007186 10.14 SCT PPARG HRH2 GRP GHRL GAST
3 positive regulation of gene expression GO:0010628 10.07 TP53 TNF IL1B HRAS CXCL8
4 fatty acid metabolic process GO:0006631 9.93 PTGS2 PTGS1 PPARG CYP2C19
5 response to lipopolysaccharide GO:0032496 9.91 S100A8 PTGS2 IL1B IL10
6 immune response GO:0006955 9.91 TNF IL1RN IL1B IL10 HRH2 DEFB4A
7 cellular response to lipopolysaccharide GO:0071222 9.9 TNF IL1B IL10 CXCL8
8 chemotaxis GO:0006935 9.89 S100A8 HRAS DEFB4A CXCL8
9 regulation of cell proliferation GO:0042127 9.89 TP53 TNF PTGS2 PTGS1 GHRL
10 positive regulation of DNA-binding transcription factor activity GO:0051091 9.85 TNF PPARG IL1B IL10
11 negative regulation of interleukin-6 production GO:0032715 9.84 TNF IL10 GHRL
12 regulation of blood pressure GO:0008217 9.83 PTGS2 PTGS1 PPARG
13 positive regulation of interferon-gamma production GO:0032729 9.82 TNF IL1B HRAS
14 response to organic substance GO:0010033 9.81 TNF PTGS2 PPARG IL10
15 inflammatory response GO:0006954 9.8 TNF S100A8 PTGS2 PTGS1 IL1RN IL1B
16 negative regulation of osteoblast differentiation GO:0045668 9.79 TNF PPARG MEN1
17 positive regulation of nitric oxide biosynthetic process GO:0045429 9.76 TNF PTGS2 IL1B
18 negative regulation of mitotic cell cycle GO:0045930 9.74 TP53 TNF IL10
19 response to glucocorticoid GO:0051384 9.73 TNF PTGS2 IL1RN IL10
20 decidualization GO:0046697 9.7 PTGS2 MEN1 GHRL
21 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.68 TP53 TNF
22 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.68 IL1RN IL10
23 cyclooxygenase pathway GO:0019371 9.68 PTGS2 PTGS1
24 response to molecule of bacterial origin GO:0002237 9.68 IL10 CXCL8
25 regulation of establishment of endothelial barrier GO:1903140 9.67 TNF IL1B
26 response to salt stress GO:0009651 9.67 TP53 TNF
27 endothelial cell apoptotic process GO:0072577 9.65 TNF IL10
28 positive regulation of lipid catabolic process GO:0050996 9.65 SCT IL1B
29 gastric acid secretion GO:0001696 9.65 HRH2 GHRL
30 embryonic digestive tract development GO:0048566 9.65 TNF SCT CXCL8
31 positive regulation of prostaglandin biosynthetic process GO:0031394 9.64 PTGS2 IL1B
32 vascular endothelial growth factor production GO:0010573 9.63 TNF IL1B
33 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.63 TNF IL1B IL10
34 negative regulation of cytokine production involved in immune response GO:0002719 9.62 TNF IL10
35 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.62 TP53 TNF PPARG IL10
36 sequestering of triglyceride GO:0030730 9.58 TNF IL1B
37 negative regulation of telomerase activity GO:0051974 9.58 TP53 PPARG MEN1
38 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.56 TNF IL1B
39 cytokine-mediated signaling pathway GO:0019221 9.5 TP53 TNF PTGS2 IL1RN IL1B IL10
40 positive regulation of fever generation GO:0031622 9.33 TNF PTGS2 IL1B
41 negative regulation of cell proliferation GO:0008285 9.23 TP53 PTGS2 PPARG MEN1 IL1B IL10

Molecular functions related to Peptic Ulcer Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region sequence-specific DNA binding GO:0000976 9.56 TP53 TNF PPARG MEN1
2 arachidonic acid binding GO:0050544 9.16 S100A8 PPARG
3 cytokine activity GO:0005125 9.02 TNF IL1RN IL1B IL10 CXCL8
4 prostaglandin-endoperoxide synthase activity GO:0004666 8.96 PTGS2 PTGS1

Sources for Peptic Ulcer Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....